Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-24
    E.g., 2018-09-24



51716 items
3:29 PM, Sep 21, 2018  |  BC Extra | Company News

Management tracks: Ex-MiMedx execs to lose compensation

MiMedx Group Inc. (NASDAQ:MDXG) said it will treat four resignations announced this summer, including that of former Chairman and CEO Parker Petit, as "for cause" terminations. The regenerative medicine and biologics company said the decision,...
3:27 PM, Sep 21, 2018  |  BC Extra | Preclinical News

Stanford team identifies human skeletal stem cells

The discovery of self-renewing human skeletal stem cells by Stanford University researchers takes the field one step closer to the development of regenerative therapies for skeletal disorders. In a paper published on Thursday in Cell, the...
3:15 PM, Sep 21, 2018  |  BC Extra | Clinical News

GTx shares crater after incontinence readout

GTx Inc. (NASDAQ:GTXI) shed 92% of its value Friday, falling from the small cap band to trading at roughly the value of its cash, after the company's enobosarm (GTx-024) failed in the Phase II ASTRID...
2:57 PM, Sep 21, 2018  |  BC Extra | Clinical News

Innovent reports Chinese NET, NSCLC data for PD-1 mAb

Innovent Biologics Inc. (Suzhou, China) presented data this week from neuroendocrine tumor and non-small cell lung cancer cohorts in its Chinese Phase Ib trial of anti-PD-1 mAb sintilimab (IBI308). Data were presented at the Chinese...
2:45 PM, Sep 21, 2018  |  BC Extra | Company News

CHMP backs Luxturna, Lilly's migraine mAb, antibiotic Vabomere

EMA's CHMP Friday recommended several therapies for approval, including gene therapy Luxturna voretigene neparvovec, migraine mAb Emgality galcanezumab and antibiotic Vabomere meropenem/vaborbactam. CHMP also confirmed its negative opinion for Exondys eteplirsen from Sarepta Therapeutics (NASDAQ:SRPT) for...
12:33 PM, Sep 21, 2018  |  BC Extra | Politics & Policy

FDA panel to discuss how patients can improve medical device review

FDA's Patient Engagement Advisory Committee (PEAC) will meet Nov. 15 to discuss how the agency can incorporate patient-generated data from online and mobile platforms such as social media, digital health technology and patient registries into...
6:33 AM, Sep 21, 2018  |  BC Extra | Financial News

Follow-on roundup: CRISPR, Viking, Fate, Molecular Templates

CRISPR Therapeutics AG (NASDAQ:CRSP), Viking Therapeutics Inc. (NASDAQ:VKTX), Fate Therapeutics Inc. (NASDAQ:FATE) and Molecular Templates Inc. (NASDAQ:MTEM) each priced follow-ons late Thursday, raising a total of $545.9 million. CRISPR raised $200 million through the sale of...
4:00 AM, Sep 21, 2018  |  BC Extra | Financial News

uBiome moving into therapeutics with $83M series C

Microbiome tech and diagnostic company uBiome Inc. (San Francisco, Calif.) raised $83 million in a series C round led by OS Fund to expand into drug research and development using its patented microbiome assets. Also...
4:53 PM, Sep 20, 2018  |  BC Extra | Financial News

First-day pop for Y-mAbs after upsized $96M IPO

Cancer company Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) gained $8 (50%) to $24 on Friday after raising $96 million through the sale of 6 million shares at $16 in an IPO. BofA Merrill Lynch, Cowen, Canaccord Genuity...
4:14 PM, Sep 20, 2018  |  BC Extra | Company News

Celenex takeout first of several planned gene therapy deals for Amicus

Just weeks after gaining its first FDA approval, Amicus Therapeutics Inc. (NASDAQ:FOLD) has announced its entrance into the gene therapy space with the acquisition of Nationwide Children's Hospital spinout Celenex (Columbus, Ohio) for $100 million...